Marker Therapeutics (Marker Therapeutics) Net Cash per Share : $1.35 (As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Marker Therapeutics Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Marker Therapeutics's Net Cash per Share for the quarter that ended in Dec. 2023 was $1.35.

The historical rank and industry rank for Marker Therapeutics's Net Cash per Share or its related term are showing as below:

MRKR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.99 Med: 4.34 Max: 23.77
Current: 3.04

During the past 13 years, the highest Price-to-Net-Cash Ratio of Marker Therapeutics was 23.77. The lowest was 2.99. And the median was 4.34.

MRKR's Price-to-Net-Cash is ranked better than
60.16% of 871 companies
in the Biotechnology industry
Industry Median: 4.07 vs MRKR: 3.04

Marker Therapeutics Net Cash per Share Historical Data

The historical data trend for Marker Therapeutics's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marker Therapeutics Net Cash per Share Chart

Marker Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

Get a 7-Day Free Trial

9.10

0.61

2.19

-0.36

1.35

Marker Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Cash per Share	Get a 7-Day Free Trial															-0.36	-0.64	1.73	1.67	1.35

Competitive Comparison of Marker Therapeutics's Net Cash per Share

For the Biotechnology subindustry, Marker Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marker Therapeutics's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marker Therapeutics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Marker Therapeutics's Price-to-Net-Cash falls into.

Marker Therapeutics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Marker Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(15.111	-	3.075	-	0)	/	8.9
=	1.35

Marker Therapeutics's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

	Net Cash per Share (Q: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(15.111	-	3.075	-	0)	/	8.9
=	1.35

Marker Therapeutics (NAS:MRKR) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Marker Therapeutics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Marker Therapeutics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Marker Therapeutics (Marker Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (NAS:MRKR) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

GX1:Germany

Address

4551 Kennedy Commerce Drive, Houston, TX, USA, 77032

Website

http://www.markertherapeutics.com

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Executives

Eliot M Lurier	officer: Interim CFO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Katharine Knobil	director	C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Frederick Gerald Wasserman	director	4 NOBADEER DRIVE, PENNINGTON NJ 08534
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker	director	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Peter L. Hoang	director, officer: CEO and President	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Norman David Eansor	director	8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani	director	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett	10 percent owner
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Juan Vera	director	2925 RICHMOND AVENUE, SUITE 1274, HOUSTON TX 77098